

1 **CD39 REGULATES P2RX7-MEDIATED LUNG NECROTIC LESIONS IN**
2 **SEVERE EXPERIMENTAL TUBERCULOSIS**

3 Gislane Almeida-Santos^{1,9*}, Igor Santiago-Carvalho^{1,10}, Fabrício Moreira Almeida²,
4 Caio César Barbosa Bomfim^{1,11}, Juan Carlo Santos e Silva⁴, Deborah Giovanna
5 Cantarini¹, Camila Ramos Silva⁸, Martha Simões Ribeiro⁸, Bruna de Gois
6 Macedo^{1,10}, Paulo Henrique Lisboa Raeder¹, Joaquim Teixeira-Xavier Junior¹, José
7 Maria Alvarez¹, Mario Hiroyuki Hirata⁴; Robson Coutinho-Silva⁵, Simon C.
8 Robson^{6,7}, Eduardo Pinheiro Amaral^{3#}, Elena Lasunskaja^{2#} and Maria Regina
9 D'Império Lima^{1*#}

10 **Author Affiliations:**

11 ¹Universidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB),
12 Departamento de Imunologia, São Paulo, Brazil. ²Laboratório de Biologia do
13 Reconhecer, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos
14 dos Goytacazes, Rio de Janeiro, Brazil. ³Inflammation and Innate Immunity Unit,
15 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and
16 Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
17 ⁴USP, Faculdade de Ciências Farmacêuticas (FCF), Departamento de Análises
18 Clínicas e Toxicológicas, São Paulo, Brazil. ⁵Instituto de Biofísica Carlos Chagas
19 Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. ⁶Harvard
20 Medical School, Boston, Massachusetts, USA. ⁷Beth Israel Deaconess Medical
21 Center, Boston, Massachusetts, USA. ⁸Instituto de Pesquisas Energéticas e
22 Nucleares (IPEN) ⁹Current location: Carter Immunology Center, Division of
23 Infectious Diseases and International Health, University of Virginia School of
24 Medicine, Charlottesville, VA, USA. ¹⁰Current location: Department of Immunology,

25 Mayo Clinic, Scottsdale, Arizona, US. ¹¹Institute of Pharmacology and Structural
26 Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.

27 **Correspondence:**


28 *Gislane de Almeida-Santos and Maria Regina D'Império Lima: Address: Av. Prof.
29 Lineu Prestes, 1730, 05508-000, São Paulo, Brazil. E-mail: gislane.almeida@usp.br
30 (G.A.S.) and relima@usp.br (M.R.D.L.). Phone: (+55) (011) 3091-7389.

31 #Senior authors

32 **SUMMARY**

33 Tuberculosis induces diverse lesions, such as necrotic pneumonia, contributing to
34 disease progression and transmission. Despite advances in understanding the role
35 of ATP-gated P2RX7 ion channels in developing severe forms of tuberculosis, the
36 regulation of this important signaling pathway remains unclear. Herein, we show that
37 the ectonucleotidase CD39 plays an essential regulatory role in TB progression by
38 preventing lung tissue damage, bacterial dissemination, and excessive inflammatory
39 responses. Mechanistically, through its enzymatic activity on the cellular surface,
40 CD39 protects infected macrophages from undergoing necrotic death mediated by
41 P2RX7 activation. We proposed that by protecting macrophages from P2RX7-
42 mediated cell death and bacterial dissemination, CD39 prevents the development of
43 necrotic lesions. Altogether, these findings uncover a significant role for CD39 as an
44 essential component of the molecular regulation underlying the development of
45 severe tuberculosis.

46 **GRAPHICAL ABSTRACT**



47

48 **Brief:** In tuberculosis, necrotic granuloma-like structures release extracellular ATP
49 (eATP), which triggers P2RX7-mediated immune cell death. CD39 degrades eATP,
50 preventing P2RX7 activation and promoting macrophage survival, thereby limiting
51 inflammation, tissue damage, and bacterial dissemination.

52 INTRODUCTION

53 Tuberculosis (TB), a disease caused by *Mycobacterium tuberculosis* (Mtb),
54 continues to be one of the significant global health challenges, with an estimated
55 10.8 million cases and 1.25 million deaths in 2023 (1). The severe pulmonary form
56 of the TB disease is triggered by the uncontrolled intracellular bacterial multiplication
57 and, consequently, necrotic death of infected myeloid cells, leading to extensive
58 tissue necrosis. Thus, facilitating pathogen transmission (2).

59 Macrophage necrosis during Mtb infection is considered a pivotal component in
60 promoting disease progression and is detrimental to the host. Unlike apoptosis,
61 where the cell contents are contained, necrosis releases intracellular components,
62 including bacteria, into the extracellular milieu. This process not only promotes the
63 dissemination of Mtb but also exacerbates inflammation by releasing damage-
64 associated molecular patterns (DAMPs), further contributing to tissue damage and
65 the formation of necrotic granulomas (3, 4). Necrotic death in Mtb-infected
66 macrophages has been linked to the activation of multiple regulated necrotic death
67 modalities, such as pyroptosis, necroptosis, and ferroptosis, all of each known to
68 drive exacerbation of the host inflammatory response (5-7). In addition, studies have
69 shown that macrophages undergoing necrosis fail to effectively control bacterial
70 replication, leading to increased bacterial burden in the lungs and worsening tissue
71 damage (8, 9). These combined effects are a hallmark of advanced disease, where
72 the immune system fails to eradicate the infection and instead causes irreversible
73 lung damage (10, 11). Thus, macrophage necrosis in TB represents a detrimental
74 pathway that not only benefits Mtb survival but also drives pathological tissue
75 destruction.

76 Our previous study has shown that sustained P2RX7 signaling, intensified by high
77 levels of extracellular ATP (eATP), detrimentally affects the progression of TB in
78 mice (12), particularly in cases involving a hyperinflammatory condition induced by
79 hypervirulent mycobacterial strains (13). This evidence suggests that the eATP-
80 P2RX7 axis exacerbates tissue damage under intense cellular stress triggered by
81 the infection. Consistent with this idea, the inhibition of P2RX7 during the acute

82 phase of TB has been shown to improve disease outcome as evidenced by optimal
83 activation of host immune defense against *Mtb*, non-necrotic granuloma formation,
84 and reduced pathogen dissemination to other organs (14).

85 Interestingly, the enzymatic activity of CD39 in degrading eATP has been proposed
86 as an essential regulatory mechanism of the immune response during infection and
87 cancer (15-17). In this context, CD39 hydrolyzes ATP to adenosine diphosphate
88 (ADP) and adenosine monophosphate (AMP), which further degrade to adenosine
89 (18). Previous studies have shown that CD39 exhibits a protective effect on
90 preventing liver necrosis by negatively regulating P2RX7-mediated cell death (19).
91 CD39 expression on regulatory T cells and CD4⁺ T cells has been shown to impair
92 macrophage activation and bacterial clearance during TB, contributing to immune
93 evasion (20, 21). Moreover, purinergic signaling through CD39 has been implicated
94 in modulating the balance between pro- and anti-inflammatory responses during *Mtb*
95 infection, which can alter the course of disease progression (22). Although these
96 findings suggest a potential role for CD39 in TB pathogenesis, its direct involvement
97 in regulating macrophage cell death and host immune responses during *Mtb*
98 infection remains unclear. In this study, we uncovered the effects of CD39 activity
99 on lung immunopathology and its robust association with necrotic lesions during TB.
100 Our data strongly indicate that CD39 expression on immune cells, particularly
101 macrophages, reduces lung necrosis and bacterial dissemination and enhances
102 survival in mice. This underscores the potential of targeting eATP signaling to
103 diminish the widespread necrotic cell death and exacerbated host inflammatory
104 response that worsens TB progression.

105 **RESULTS**


106 **The expression of genes encoding CD39 and P2RX7 is highly correlated with** 107 **active forms of TB in mice and human patients**

108 To evaluate the expression of purinergic genes during Mtb infection, we analyzed
109 publicly available datasets of whole and peripheral blood samples of patients with
110 active TB (23-25). Meta-analysis of *ENTPD1* (CD39) gene expression was
111 performed revealing a strong upregulation of the gene compared to healthy subjects
112 in all eight independent reports evaluated (Fig. 1A). Furthermore, enhanced
113 expression of *P2RX7* gene was found in five of these reports, demonstrating a robust
114 correlation between these two genes during Mtb infection. We failed to see
115 differences in the expression of other genes related to the purinergic pathway
116 (*ENTPD1-3*, *NT5E*, and *ADORA1,2b,3*) in patients with active TB. To determine
117 whether this response depends on disease activity, we also analyzed a publicly
118 available RNA-seq dataset (26). *ENTPD1* and *P2RX7* expression was found to be
119 increased in the blood of active TB patients compared to healthy controls and
120 subjects with latent TB infection (LTBI) (Fig. 1B). No significant difference was
121 observed between LTBI and healthy controls, suggesting that *ENTPD1* and *P2RX7*
122 upregulation is associated with active forms of the disease.

123 To determine whether the transcriptional signature observed in humans is
124 recapitulated in mouse models, the mRNA expression of *Entpd1* and *P2rx7* genes
125 were analyzed in publicly available datasets of the blood and lungs of C57BL/6 (WT)
126 mice infected with mycobacteria (26). The transcriptional mRNA levels of *Entpd1*
127 and *P2rx7* genes were found augmented in both blood and lungs of Mtb-infected

128 mice compared to naïve animals, similarly, to seen in human disease (Fig. 1C and
129 1D). These findings suggest the upregulation of genes encoding CD39 and P2RX7
130 as biomarkers for active TB and more specifically indicate their use to infer the
131 development of severe disease.

132 To overview CD39 and P2RX7 gene expression across different cell subtypes in the
133 infected lung, we analyzed a public high-throughput single-cell mRNA sequencing
134 on granulomas from non-human primates (NHP) at 4 weeks p.i. (27). A Cell Type
135 Annotation analysis showed a higher mRNA expression of *ENTPD1* on endothelial
136 cells and macrophages than on other immune and non-immune cells (Fig. 1E).
137 Interestingly, *P2RX7* expression was slightly increased on endothelial cells,
138 macrophages and mast cells within the granuloma (Fig. 1E). Importantly, among all
139 cell subtypes, macrophages were the most abundant population (Fig. 1F) and the
140 cell type showing the higher *ENTPD1* and *P2RX7* coexpression (Fig. 1G).




142 **Figure 1. CD39 and P2RX7 gene expression correlate with active tuberculosis (TB) in mice, human patients, and NHP.**

143 A) Expression levels of purinergic genes (*ENTPD1*-CD39, *P2RX7*-P2RX7, *ENTPD1*-3, *NT5E*, and *ADORA1,2b,3*) in whole
144 and peripheral blood samples from patients with active TB were analyzed using publicly available datasets. B) Comparative
145 analysis of *ENTPD1* and *P2RX7* gene expression in blood samples from patients with active TB, latent TB infection (LTBI),
146 and healthy controls derived from publicly available RNA-seq datasets. C & D) Transcriptional levels of *Entpd1* and *P2rx7* (CD)
147 of mice infected with *Mycobacterium tuberculosis* (H37Rv Mtb strain) compared to non-infected (naïve) mice, using publicly
148 available RNA-seq datasets. E) Cell Type Annotation analysis in granulomas from non-human primates, based on public high-
149 throughput single-cell mRNA sequencing datasets. F & G) UMAP plots showing the distribution of immune cell populations (F)
150 and the co-expression of *P2rx7* and *Entpd1* across these populations (G) in granulomas from non-human primates.

151 **CD39 deficiency aggravates pulmonary necrosis caused by hypervirulent**
152 **mycobacteria**

153 We previously defined that P2RX7 signaling promotes the development of necrotic
154 lesions in mice infected with highly virulent mycobacteria (12). To investigate the role
155 of CD39 on severe TB, we infected *Entpd1*^{-/-} and their WT littermates with the highly
156 virulent Beijing M299 Mtb clinical isolate due to its ability to trigger necrotic lung
157 pathology in WT mice. (12, 28). *Entpd1*^{-/-} mice had anticipated and accentuated
158 weight loss compared to WT mice (Fig. 2A). Additionally, all *Entpd1*^{-/-} mice died
159 within 18 to 27 days p.i. (Fig. 2B). At the same time, 87.5% of the WT mice remained
160 alive during a 42-day p.i. period. Lungs collected 21 days p.i. showed 200-fold
161 increase in the bacterial burden in *Entpd1*^{-/-} mice compared to WT mice (Fig. 2C).
162 Notably, increased presence of lung white nodules was observed in *Entpd1*^{-/-} mice
163 compared to WT mice (Fig. 2D). Histopathological analysis of the lungs
164 demonstrated extensive necrotic lesions and areas of alveolitis and edema in
165 *Entpd1*^{-/-} mice (Fig. 1E and 1F). In contrast, initial necrotic areas surrounded by
166 alveolitis were observed in WT mice. These results suggest that the expression of

167 CD39 suppresses the development of severe lung disease as evidenced by reduced
 168 necrotic pneumonia and mortality in mice infected with highly virulent Mtb.



169

170 **Figure 2. CD39 deficiency exacerbates pulmonary necrosis induced by hypervirulent Mycobacterium tuberculosis**
 171 **(Mtb).** C57BL/6 wild-type (WT) and CD39-deficient (*Entpd1^{-/-}*) mice were infected with the hypervirulent M299 Mtb strain. A)
 172 Percentage change in body weight relative to baseline (day 0). B) Survival curve of infected mice, where animals were
 173 euthanized upon reaching a >20% loss in body weight to comply with humane endpoint criteria. C) Colony-forming units (CFU)
 174 in lung homogenates. D) Gross macroscopic pathology of the left lung at day 21 of infection. E) Hematoxylin and Eosin staining
 175 of lung sections. F) Ziehl-Neelsen staining of lung sections. Necrotic spots are marked with an asterisk (*), and areas of
 176 alveolitis are indicated by a hash symbol (#). Significant differences between groups are indicated by $p < 0.05$, as determined
 177 by the Mann-Whitney non-parametric test. Data represent results from two independent experiments, with five mice per group.

178 **The expression of CD39 in the immune cells protects against severe TB**

179 To understand if the protective effect of CD39 activity was associated with its
180 expression on immune or epithelial cells, we next evaluated the protein levels of
181 CD39 and P2RX7 on immune (CD45⁺) or non-immune (CD45⁻) lung compartments
182 of WT mice following M299 Mtb infection. The results revealed the accumulation of
183 immune cells in the infected lungs (Fig. 3A), which showed increased proportion and
184 expression of CD39 and P2RX7 compared with non-immune cells (Fig. 3B and 3C).
185 Next, we evaluated whether the expression of CD39 in the immune compartment
186 was required for protection against severe TB using *WT>CD45.1* (WT) and *Entpd1*⁻
187 */>CD45.1* bone marrow mouse chimeras. *Entpd1*⁻*>CD45.1* mice were more
188 susceptible to infection and showed accentuated body weight loss at day 21 p.i.
189 compared to *WT>CD45.1* (Fig. 3D). The lung weight and bacterial burden in *Entpd1*⁻
190 */>CD45.1* mice were also increased compared to *WT>CD45.1* mice (Fig. 3E and
191 3F). Enlarged lung white nodules were found in infected *Entpd1*⁻*>CD45.1* mice (Fig.
192 3G), which showed larger necrotic lesions with extracellular bacteria compared to
193 *WT>CD45.1* mice (Fig. 3H). Together, the results suggest that the expression of
194 CD39 on hematopoietic compartment is critical to control the development of
195 necrotic lesions and bacterial spread.





Figure 3. The expression of CD39 in the immune cells protects against severe TB. C57BL/6 (WT) mice, as well as WT>CD45.1 (WT) and *Entpd1*^{-/-}>CD45.1 bone marrow mouse chimeras, were infected with the M299 Mtb strain. A) Distribution of immune (CD45⁺) and non-immune (CD45⁻) cells in the lungs of naïve and infected WT mice. Mice were analyzed on day 21 of infection. B & C) Median intensity fluorescence (MFI) of CD39 and P2RX7 expression in CD45⁺ and CD45⁻ lung cells described in A. D) Percentage changes in body weight relative to baseline (day 0) in infected mouse chimeras. E & F) Lung weights and colony-forming units (CFUs) in lung homogenates of infected mouse chimeras on day 21 of infection. G) Gross macroscopic pathology of the left lung in mouse chimeras on day 21 of infection. H) Histopathological analysis with Ziehl-Neelsen staining of lung sections of mouse chimeras at 21 days of infection. Significant differences between groups are indicated by $p < 0.05$, when * represents $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, as determined by the Mann-Whitney non-parametric test. The data represent results from two independent experiments, with five mice per group.

197 **The ablation of CD39 results in lower numbers of macrophages and dendritic**
198 **cells while increasing the inflammatory response in infected lungs**

199 To investigate which immune cell population could be responsible for the protective
200 role of CD39 in preventing TB severity, we evaluated the expression of CD39 and
201 P2RX7 in macrophages, neutrophils, monocytes, dendritic cells and T cells from the
202 lungs of infected WT mice. Macrophages exhibited the highest expression levels of
203 both molecules (Fig. 4A and 4B), as observed in the single-cell analysis of
204 granulomas from non-human primates (Fig. 1E-G).

205 Next, we investigated the impact of CD39 deficiency on the inflammatory response
206 in WT and *Entpd1*^{-/-} infected lungs. We have previously demonstrated that CD4⁺ T
207 cell response in the lung parenchyma plays an essential role in the severity of TB
208 caused by highly virulent strains (29). We observed decreased numbers of CD4⁺ T
209 cells in the lung of *Entpd1*^{-/-} mice compared to WT mice. However, there were no
210 differences in the numbers of parenchymal CD44⁺CD4⁺ T (CD45 i.v.⁻) or
211 intravascular (CD45 i.v.⁺) CD44⁺CD4⁺ T or CD44⁻CD4⁺ T cells when comparing
212 infected WT and *Entpd1*^{-/-} mice (Sup. Fig. 1). Despite the increase in the absolute
213 CD11b⁺ number per lung of myeloid cells in infected *Entpd1*^{-/-} mice (Fig. 4C) the
214 absolute number per lung of macrophages and dendritic cells were reduced
215 compared to infected WT mice (Fig. 4D-F). At the same time, neutrophil and
216 monocyte populations augmented in the absence of CD39 (Fig. 4D, 4G and 4H). In
217 addition, we observed increased levels of cytokines implicated in the necrotic
218 process (IL-1 α and IL-1 β), cell migration (CCL2, CCL3, and CCL4), and effector T
219 cell response (IFN- γ , TNF- α , IL-17) in lung homogenates of infected *Entpd1*^{-/-} mice

220 (Fig. 4I). These findings suggest that the lack of CD39 leads to the depletion of
 221 macrophages and dendritic cells while promoting the inflammatory response against
 222 TB.



223 **Figure 4. CD39 deficiency reduces macrophage and dendritic cell populations, promoting inflammation in the Mtb-**
224 **infected lung.** A) Histograms showing a qualitative comparison of CD39 and P2RX7 protein expression levels across immune
225 cell subsets isolated from the lungs of Mtb-infected WT mice. B) Heatmap illustrates the Geometric Mean Fluorescence
226 Intensity (GMFI) of P2RX7 and CD39 across immune populations in the infected WT lungs. C) tSNE plots depicting the
227 distribution of macrophages (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁻, CD68⁺, CD64⁺), dendritic cells (Live/Dead⁻, DUMP⁻, CD45⁺,
228 Ly6G⁻, CD68⁻, CD64⁻, CD11b⁺, MHCII⁺), monocytes (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁻, MHCII⁻, SSCLow, Ly6C⁺), and
229 neutrophils (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁺) within the Myeloid cell (Live/Dead⁻, DUMP⁻, CD45⁺) population. D-H)
230 Absolute numbers of myeloid cells, dendritic cells, macrophages, monocytes, and neutrophils in infected and non-infected WT
231 and *Entpd1*^{-/-} mice. I) Cytokine and chemokine levels in lung homogenates of infected WT and *Entpd1*^{-/-} mice. Significant
232 differences between groups are indicated by p < 0.05. Significance levels are represented as follows: p < 0.05 (*), p < 0.01
233 (**), p < 0.001 (***), and p < 0.0001 (****), determined by the Mann-Whitney non-parametric test. The data represent results
234 from two independent experiments with five mice per group.


235 **CD39 deficiency leads to an increased macrophage death and inflammasome** 236 **activation in Mtb-infected *Entpd1*^{-/-} mice**

237 To assess whether the low macrophage numbers and high IL-1 β levels in the lungs
238 of infected *Entpd1*^{-/-} mice were associated with increased cell death and
239 inflammasome activation, we analyzed the lung myeloid cell population according to
240 cell viability and caspase-1 activation. A percentage reduction of live cells (Live and
241 Dead⁻) and increase of active caspase-1⁺ dead cells (Live and Dead⁺) was observed
242 in infected *Entpd1*^{-/-} mice compared to infected WT mice (Fig. 5A-C), while there was
243 no difference in the active caspase-1⁺ live population (Fig. 5A-D). Of note, a
244 population of dead cells expressing high levels of active caspase-1 became evident
245 only in the absence of CD39. These results indicate that CD39 prevents
246 inflammasome activation and myeloid cell death, possibly by a mechanism
247 dependent on pyroptosis.

248 To determine whether the caspase 1-associated myeloid cell death in infected
249 *Entpd1*^{-/-} lungs was linked to DNA fragmentation, we stained lung histological

250 sections using the TUNEL method. Considering both the number of positive cells
251 and the mean fluorescence intensity (MFI), a higher level of DNA damage was
252 observed in infected lungs of *Entpd1*^{-/-} mice compared to WT mice (Fig. 5E-G). This
253 finding, combined with the increase of dead myeloid cells expressing high levels of
254 active caspase-1+ (Fig. 5A), suggests an inflammasome-driven cell death, possibly
255 via pyroptosis or secondary apoptosis, contributing to enhance DNA fragmentation
256 when TB develops in the absence of CD39.

257 To specifically assess the role of CD39 in Mtb-induced macrophage killing, we
258 compared bone marrow-derived WT and *Entpd1*^{-/-} macrophages (BMDMs). The
259 absence of CD39 resulted in 25% fewer viable BMDMs following infection (Fig. 5H
260 and 5I) and a significant reduction in the absolute number of these cells (Fig. 5J).
261 Suggesting that infected *Entpd1*^{-/-} BMDMs were more susceptible to cell lysis,
262 culture supernatants of these cells showed an increase in the numbers of
263 extracellular mycobacteria and higher levels of lactate dehydrogenase (LDH), a
264 marker of membrane integrity loss (Fig. 5K and 5L). These findings highlight the
265 critical role of CD39 in regulating macrophage survival during Mtb infection and thus
266 in limiting extracellular bacterial spread.




268 **Figure 5. CD39 expression prevents caspase-1 activation, macrophage death, and extracellular bacterial release.** A)
269 Dot plots of viability staining (Live and Dead) and active caspase-1 staining in myeloid (Live/Dead⁻, DUMP⁻, CD45⁺) cells from
270 the lungs of Mtb-infected WT and *Entpd1*^{-/-} mice. B-D) Percentages of live cells, live active caspase 1⁺ cells, and dead active
271 caspase 1⁺ cells in mice described in A. E) Tunnel staining in WT and *Entpd1*^{-/-} mice lung histological sections at day 21 of
272 infection. F) Number of Tunnel⁺ cells/field in mice described in E. G) Mean Fluorescence Intensity (MFI) of Tunnel staining/field
273 in mice described in A. Each dot represents the mean of six fields per mouse. H) Histograms of viability staining (Live and
274 Dead) in bone marrow-derived macrophages (BMDM) from WT or *Entpd1*^{-/-} mice after 24h post-infection *in vitro* with an MOI
275 of 10. I and J) Percentage of dead cells and absolute number of live cells per well in BMDM cultures described in H. K)
276 Extracellular CFU and percentage of LHD release in the supernatant of infected BMDM cultures described in H. Data
277 represents two independent experiments. Significant differences between groups are indicated by $p < 0.05$. Significance levels
278 are described as follows: $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****), determined by the Mann-Whitney
279 non-parametric test.

280 **P2RX7 inhibition attenuates the effects of CD39 deficiency *in vivo* and *in vitro*,**
281 **promoting macrophage survival and preventing necrotic lesions and bacterial**
282 **dissemination**

283 It is known that CD39 can regulate macrophage death and the release of pro-
284 inflammatory cytokines induced by P2RX7 signaling (19, 30). Therefore, we next
285 investigated whether the protective effect of CD39 on Mtb-infected killing resulted
286 from its ability to degrade eATP and prevent P2RX7 signaling. The inhibition of
287 P2RX7 with A740003 was able to rescue approximately 35% of *Entpd1*^{-/-} BMDM
288 viability after M299 infection using a MOI of 10 (Fig. 6A). A similar difference was
289 observed in the absolute number of live cells per culture (Fig. 6B). As evidence of
290 the protective effect of P2RX7 inhibition on necrotic death of these cells, a lower
291 number of extracellular CFUs was determined in the supernatants of A740003-
292 treated infected *Entpd1*^{-/-} BMDMs (Fig. 6C). These findings indicate that CD39
293 impairs P2RX7-triggered macrophage death induced by highly virulent
294 mycobacteria.

295 The critical role of CD39 in protecting against the development of necrotic lesions
296 and bacterial spread in severe TB may also result from its ability to reduce the eATP
297 sensing by P2RX7. To test this hypothesis, we inhibited P2RX7-signaling
298 pharmacologically *in vivo*. *Entpd1*^{-/-} mice were treated with the P2RX7 inhibitor
299 Brilliant Blue G (BBG) every two days from day 14 to 21 p.i. when the mice started
300 to lose weight, as previously reported (14). At day 21 p.i., mice treated with the
301 P2RX7 inhibitor showed less body weight loss compared to untreated animals (Fig.
302 6D). Importantly, inhibition of P2RX7 in *Entpd1*^{-/-} mice increased resistance to Mtb
303 infection, as evidenced by reduced bacterial burden, lung weight, and the number
304 and size of white nodules in the lung (Fig. 6E-G). Following these findings, the
305 population of lung macrophages was increased after BBG treatment (Fig. 6H-I). In
306 addition, because of P2RX7 inhibition, the histopathological analysis showed a
307 significant reduction in pulmonary necrosis areas associated with extracellular
308 bacteria (Fig. 6J). These results show that the beneficial effects of CD39 in
309 suppressing the development of severe forms of TB in mice are primarily mediated
310 by its ability to prevent eATP sensing by P2RX7.



311

312 **Figure 6. P2RX7 inhibition attenuates the effects of CD39 deficiency *in vivo* and *in vitro*.** (A) Histograms showing viability
 313 staining (Live and Dead) of bone marrow-derived macrophages (BMDMs) from *Entpd1*^{-/-} mice treated or not with the P2RX7
 314 inhibitor Brilliant blue G (BBG). Cells were maintained in culture for 24h post-infection (p.i.) with an MOI of 10. B) Absolute
 315 numbers of BMDMs in cultures described in A. C) Extracellular colony-forming units (CFUs) in the supernatants of infected
 316 BMDM cultures described in A. The data represents two independent experiments. D) Percentage changes in body weights
 317 of infected *Entpd1*^{-/-} mice treated or not with BBG relative to baseline (day 0). E and F) CFUs of M299 Mtb in lung homogenates
 318 and lung weights of mice at 21 days of infection. G) Gross macroscopic pathology of the left lung of mice at 21 days of infection.

319 H and I) Contour plots and absolute numbers of lung macrophages of mice at 21 days of infection. J) Histopathological analysis
320 with Ziehl-Neelsen staining of lung sections of mice at 21 days of infection. Significant differences between groups are indicated
321 by $p < 0.05$. Significance levels are represented as follows: $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$ (***), and $p < 0.0001$ (****),
322 determined by the Mann-Whitney non-parametric test. Data represents two independent experiments with three to four mice
323 per group.

324 **DISCUSSION**

325 Necrotic pneumonia is a severe condition associated with pulmonary TB that has a
326 significant impact on disease progression and transmission by promoting pathogen
327 dissemination through lung tissue and respiratory tracts (31, 32). Despite advances
328 in understanding the role of P2RX7 in the development of severe TB pathology (12,
329 14, 29, 33), important questions related to the regulation of this pathway remain to
330 be answered. The ability of CD39 to degrade eATP and generate adenosine in the
331 extracellular environment makes this molecule a possible target for regulating
332 P2RX7 activation and the inflammatory response during TB (34, 35). Addressing
333 this issue, our study reveals a major role for CD39 in TB progression by controlling
334 P2RX7-induced death of infected macrophages and, consequently, reducing
335 necrotic lesions in the lungs and pathogen dissemination.

336 The first indication of the involvement of CD39 in the regulation of P2RX7 signaling
337 during TB was the elevated expression of *ENTPD1* and *P2RX7* genes, but not of
338 genes associated with other ecto-ATPases and adenosine signaling (*ENTPD2,3*,
339 *NT5E*, and *ADORA1,2B,3*) in peripheral blood cells of TB patients. Coexpression of
340 genes encoding CD39 and P2RX7 was also observed in NHP granuloma cells, as
341 well as in the blood and lung cells from Mtb-infected C57BL/6 mice. Since the
342 expression *ENTPD1* and *P2RX7* genes was not upregulated in peripheral blood cells
343 during latent human infection, these molecules represent potential biomarkers for

344 identification, appropriate treatment and management of active TB patients. Stimuli
345 associated with tissue damage, hypoxia (via hypoxia-inducible factor 1 (HIF1)
346 transcription factor), and inflammation can upregulate CD39 and P2RX7 expression
347 (15, 16, 36-40). Among them, cytokines with systemic activity, such as IL-1 β , IL-6
348 and TNF, as well as type I IFNs, are produced during TB (41) and may be
349 responsible for the increased expression of CD39 and P2RX7 in peripheral blood
350 cells during active disease.

351 Excessive inflammatory responses were observed in the lungs of CD39-deficient
352 mice, as evidenced by high levels of IL-1 β in the lungs and robust activation of
353 caspase-1 in myeloid cells. Of note, an increased population of dead myeloid cells
354 exhibiting intense caspase-1 activity was found in the lungs of CD39-deficient mice,
355 suggesting that CD39 protects these cells to undergoing necrosis associated with
356 inflammasome activation, as it has been reported during pyroptosis (42). Supporting
357 the concept that CD39 protects against tissue damage during TB, increased DNA
358 fragmentation was observed in the lungs when the disease developed without CD39.
359 Compelling evidence suggesting that CD39 limits TB progression by regulating
360 P2RX7 activation comes from the comparative analysis of WT and CD39-deficient
361 mice infected with hypervirulent mycobacteria and treated with a P2RX7 inhibitor.
362 CD39 deficiency promoted widespread lung pulmonary necrosis and enhanced
363 bacterial growth and dissemination, culminating in early loss of body weight and,
364 consequently, increased mortality in mice. Significantly, pharmacological P2RX7
365 blockade attenuated the progression of the disease caused by the absence of CD39.
366 A parallel finding has been described in sepsis in which P2RX7 also plays a
367 significant role in disease development (19), as reported in severe TB (12).

368 Interestingly, a similar phenotype was observed in an animal model of sepsis, in
369 which CD39 deficiency promoted P2RX7-triggered cell death, cytokine production,
370 and liver injury (19) .

371 Our results also showed that macrophages are critical players in the regulatory
372 activity of CD39 in P2RX7-mediated development of necrotic lesions in pulmonary
373 TB. Macrophages and endothelial cells of NHP granuloma exhibited high
374 transcriptional levels of genes encoding CD39 and P2RX7. Still, these genes were
375 expressed mainly in the macrophage population, considering their prevalence in this
376 tissue. Concordantly, in the lungs of Mtb-infected C57BL/6 mice, CD39 and P2RX7
377 proteins were expressed at higher levels in immune cells than structure cells,
378 particularly in macrophages that showed the highest expression of both molecules
379 within immune cells. Remarkably, the lack of CD39 restricted to the immune cell
380 compartment was sufficient to promote extensive necrotic lesions in the lungs,
381 together with increased bacterial growth and dissemination in mice infected with
382 hypervirulent mycobacteria. Importantly, a protective effect against severe TB was
383 observed in mice repopulated with immune cells that did not express P2RX7 (33).

384 It has been reported that macrophages infected with avirulent mycobacteria die
385 through apoptosis, preventing bacterial dissemination, whereas virulent
386 mycobacteria trigger necrosis of infected macrophage, thereby facilitating pathogen
387 release into the extracellular environment (11, 43, 44). In this context, we have
388 previously shown that P2RX7 signaling is critical in triggering necrotic death of
389 macrophages infected with highly virulent mycobacteria (28). Extending these
390 findings, this study demonstrated that CD39 regulates the necrotic death of infected
391 macrophages by inhibiting P2RX7 signaling. CD39 deficiency in Mtb-infected mice

392 resulted in a profound depletion of lung macrophages associated with increased
393 numbers of dead cells and release of IL-1 α and IL-1 β in the lungs. Importantly,
394 blocking P2RX7 in these animals increased the macrophage population in the lungs
395 of these mice. Our *in vitro* results also showed that infected macrophages lacking
396 CD39 were predisposed to necrotic death in a P2RX7-dependent manner. Since
397 CD39 is known to regulate the balance between cell survival and death, we postulate
398 that its deficiency leads to uncontrolled P2RX7 activation by eATP. This excessive
399 activation promotes increased necrotic death of macrophages, compromising the
400 host's ability to control the infection. Furthermore, the release of intracellular
401 contents amplifies inflammation and exacerbates tissue damage, creating a
402 permissive environment for pathogen persistence and immune dysregulation.
403 Our findings strongly suggest that CD39 shapes the development of pulmonary TB
404 by acting as a counterregulatory mechanism that limits P2RX7 signaling in infected
405 macrophages via eATP hydrolysis. Thus, CD39 protects these cells from necrotic
406 death, maintaining their immune response function and preventing the disease
407 progression. Altogether, these results provide further evidence for the critical role of
408 purinergic signaling in regulating cellular/tissue damage as well as disease
409 progression and implicate the CD39/P2RX7 axis as a potential target for host-
410 directed TB therapy.

411 **MATERIALS AND METHODS**

412 **Mice**

413 Specific pathogen-free C57BL/6 (WT) and *Entpd1*^{-/-} male (6-8-week-old) mice were
414 bred at the isogenic mouse facility, ICB, USP. After infection, mice were maintained

415 in micro isolator cages with HEPA filters at the Biosafety Laboratory Level 3, FCF,
416 USP. All procedures were performed according to national regulations and ethical
417 guidelines for mouse experimentation (permit no. 3185080318).

418 **Mycobacteria and mouse infection**

419 The Mtb strain of the Beijing genotype (strain M299), isolated from a TB patient in
420 the Maputo province, Mozambique, was kindly provided by Dr. Philip Suffys
421 (Oswaldo Cruz Foundation, FIOCRUZ, Rio de Janeiro, Brazil). Frozen aliquots were
422 thawed and grown in Middlebrook 7H9 medium enriched with 10% (vol/vol) ADC
423 (albumin, dextrose, catalase) (Difco, BD Biosciences, USA) and 0.05% (vol/vol)
424 Tween 80 (Sigma-Aldrich) and maintained at 37°C for seven days until mid-log
425 phase in constant agitation. The bacterial suspensions were sonicated in a water
426 bath and vortexed for 1 minute to disperse the lumps. The density of bacterial
427 suspensions was determined using a spectrophotometer at 600 nm. Mice were
428 anesthetized intraperitoneally (i.p.) with ketamine (Vetbrands, Brazil; 100 mg/kg) and
429 xylazine (Vetbrands; 15 mg/kg) and infected intratracheally (i.t.) with ~70-100 (lower
430 dose) or ~150-200 (double dose) bacilli of the highly virulent Mtb Beijing M299 strain
431 (28).

432 **P2RX7 inhibition to prevent cell death during lung processing**

433 Several studies describe that P2RX7 direct, or indirect activity inhibition preserves
434 cell viability during tissue processing under collagenase IV digestion (45, 46). To
435 prevent cell death during lung digestion and processing to obtain cell suspensions
436 for Flow Cytometry, infected mice were injected intravenously with brilliant blue G

437 (BBG, Sigma-Aldrich), a P2X receptor inhibitor (45 mg/Kg/mouse in 200 μ L of PBS)
438 30 minutes before the euthanasia (**Supplementary Figure 1A**). The differences in
439 the cell viability between treated and non-treated infected mice prior to euthanasia
440 are shown in **Supplementary Figures 1B-G**.

441 **Isolation and counting of lung-infiltrating cells**

442 The dissected lung lobes were washed with sterile PBS 1x, fragmented, and
443 digested with collagenase type IV (0.5 mg/mL, Sigma-Aldrich) and type IV bovine
444 pancreatic DNase (Roche Diagnostics; 1 mg/ml) in RPMI 1640 medium (Gibco,
445 USA) at 37°C for 40 minutes under agitation (200 rpm) (Almeida *et al.*, 2017). The
446 remaining lung fragments were mechanically dissociated by passage through a 100
447 μ m pore-size cell strainer and incubated with ACK Lysing Buffer (Thermo Fisher
448 Scientific, USA) at room temperature for one minute to deplete the erythrocytes. Cell
449 suspensions were washed with 10% fetal calf serum (FCS, Gibco) in PBS following
450 centrifugation at 1,200 rpm for 5 minutes and resuspended in RPMI 1640 medium.
451 Lung cell viability was determined using a trypan blue exclusion assay and a
452 hemocytometer.

453 **Phenotypic analysis of lung-infiltrating cells**

454 Isolated lung cells (1×10^6 cells/well) were seeded in round-bottom 96-well plates and
455 stained with Live/dead dye (Thermo Fisher Scientific) to determine cell viability, as
456 described in the datasheet. Lung cells were stained using fluorochrome-labeled
457 monoclonal antibodies to lineage (CD4 - RM4-5, CD8 - S3-6.7, CD19 - 1D3 and
458 NK.1 - PK136), CD11b (M1/70), Ly6G (1A8), Ly6C (AL-21), CD11c (N418), F4/80

459 (BM-8), CD39 (24DMS1), CD4 (RM4.5), CD8 (S3-6.7), CD44 (IM7) and CD69
460 (H1.2F3) (BD Biosciences) for 30 minutes at 4°C. Cells were fixed with 4%
461 paraformaldehyde for 30 minutes at 4°C and washed on a staining buffer. Cell
462 acquisition was performed using the LSRFortessa™ flow cytometer (BD Biosciences
463 – USA) and the FlowJo 10.5.3 software (BD Biosciences). The gating strategy for
464 CD11b⁺ myeloid cell analysis is shown in Supplementary Figure 1H.

465 **Lung macroscopic and microscopic analyses**

466 The harvested lung lobes were washed with sterile PBS 1x and weighed. The lung
467 relative mass was calculated by dividing the mean lung weight in experimental mice
468 by the mean in uninfected controls from their respective groups. The left lung upper
469 lobe was maintained in 10% buffer formalin for 48 hours, photographed, and
470 subsequently embedded in paraffin. Histological sections of approximately 4-5 µm
471 were stained using the hematoxylin-eosin (HE) method to visualize tissue
472 alterations, Ziehl Neelsen (ZN) method to detect the presence of acid-fast bacteria
473 (AFB), and Immunofluorescence for TUNEL Staining (Thermo Fisher Scientific), as
474 described in the datasheet, to visualize nucleus fragmentation. The samples were
475 examined with an Axioplan microscope (Carl Zeiss Inc., Germany), and the images
476 of lung sections were captured by Coolpix P995 (Nikon)-coupled device camera.

477 **Colony-forming unit (CFU) analysis and counting**

478 Corresponding bacterial concentrations in lung homogenate were determined by the
479 colony-forming unit test, using serial 10-fold dilutions of each suspension and plating
480 on Middlebrook 7H10 agar (Difco, Detroit, MI), supplemented with 0.5% glycerol,

481 10% oleic acid–albumin–dextrose–catalase enrichment, OADC (BD, Sparks, MD).
482 Plates were cultured at 37°C for 21 days, and total CFU was determined by colony
483 counting.

484 **BMDM cultures**

485 Murine BMDMs were generated by isolating undifferentiated monocytes from bone
486 marrow from both femurs and tibiae of WT and *Entpd1*^{-/-} mice. Bone marrow was
487 harvested in DMEM/F-12 (Gibco) supplemented with 10% heat-inactivated FBS
488 (Gibco) and flushed through a syringe with a 16-gauge needle. Cells were dispersed
489 with a 5-mL syringe (BD Biosciences) fitted with a 20-gauge needle. Dispersed cells
490 were seeded in culture flasks (T-175) containing 20 mL DMEM/F-12 supplemented
491 with 10% FBS, 25 µg/ml gentamicin (Gibco), and 20% of L929-conditioned media.
492 Cells were incubated at 37°C with 5% CO₂, and 20 mL of fresh medium containing
493 L929-conditioned media without gentamicin was added on day 3. On day 7,
494 macrophages were detached by the addition of cold PBS.

495 ***In vitro* BMDM infection**

496 Frozen bacterial aliquots were thawed and cultured as described above. Bacterial
497 suspensions were centrifuged at 4,000 rpm for 10 min, resuspended in DMEM/F-12,
498 sonicated for 30 s, and homogenized to reduce bacterial clumping. BMDMs were
499 exposed to M299 Mtb infection at 1:10 MOI. After 3 hours, cells were washed three
500 times with room temperature PBS and then cultured in fresh DMEM/F-12 media,
501 supplemented with 3% for 24 hours. According to the manufacturer's instructions,

502 LDH release in the supernatants from BMDM cultures was determined using the
503 CytoTox 96 nonradioactive cytotoxicity assay (Promega).

504 **Statistical analyses**

505 Statistical analyses were performed using the GraphPad Prism 7 software
506 (GraphPad, USA), and differences between groups were considered significant
507 when $p < 0.05$ (5%). ANOVA and Bonferroni post-test analyzed the simultaneous
508 effects of two factors. One-way ANOVA and Tukey test were used to evaluate the
509 impact of a single parameter.

510 **NOTES**

511 **Acknowledgements.** We thank Dr. Philip Suffys (Oswaldo Cruz Foundation,
512 FIOCRUZ, Rio de Janeiro, Brazil) for providing the Beijing M299 *M. tuberculosis*
513 strain. We also thank Rogério Silva do Nascimento, José Israel Lima, Silvana Silva
514 and Maria Áurea de Alvarenga for technical assistance.

515 **Financial support.** This study was supported in whole by São Paulo Research
516 Foundation (FAPESP-Brazil) grants: 2015/20432-8 (M.R.D.L.), 2019/24700-8
517 (I.S.C.), and 2020/09043-8 (C.C.B.B.); and by National Council for Scientific and
518 Technological Development—(CNPq) grants: 408909/2018-8 (M.R.D.L.),
519 303810/2018-1 (M.R.D.L.), 308870/2023-0 (M.R.D.L.) and 140666/2018-4 (G.A.S.).

520 **Authors' Contributions.** Conceived and designed the experiments: G.A.S., E.P.A.
521 E.L. and M.R.D.L. Performed the experiments: G.A.S.; I.S.C.; F.M.A.; C.C.B.B.;
522 D.G.C; C.R.S.; B.G.M.; P.H.L.R.; J.T.X.J; and Analyzed the data: G.A.S.; F.M.A.;

523 J.C.S.S; E.L. and M.R.D.L. Contributed reagents/materials/ analysis tools: G.A.S.;

524 M.S.R; J.M.A.; M.H.H.; R.C.S.; S.C.R.; E.L.; M.R.D.L.

525 ***Potential conflicts of interest:*** The authors have declared no conflicts of interest.

526 This study has not been previously reported and is not being considered for

527 publication elsewhere. All authors agree to submit this manuscript.

528 REFERENCES

529

- 530 1. Organization WH. Global Tuberculosis Report 2024. 2024.
- 531 2. Guirado E, Schlesinger LS, Kaplan G, editors. Macrophages in tuberculosis: friend or foe.
532 *Seminars in immunopathology*; 2013: Springer.
- 533 3. Kornfeld H, Mancino G, Colizzi V. The role of macrophage cell death in tuberculosis. *Cell*
534 *Death & Differentiation*. 1999;6(1):71-8.
- 535 4. Wong KW, Jacobs Jr WR. Critical role for NLRP3 in necrotic death triggered by
536 *Mycobacterium tuberculosis*. *Cellular microbiology*. 2011;13(9):1371-84.
- 537 5. Beckwith KS, Beckwith MS, Ullmann S, Sætra RS, Kim H, Marstad A, et al. Plasma membrane
538 damage causes NLRP3 activation and pyroptosis during *Mycobacterium tuberculosis* infection. *Nat*
539 *Commun*. 2020;11(1):2270.
- 540 6. Zhao X, Khan N, Gan H, Tzelepis F, Nishimura T, Park SY, et al. Bcl-x(L) mediates RIPK3-
541 dependent necrosis in *M. tuberculosis*-infected macrophages. *Mucosal Immunol*. 2017;10(6):1553-
542 68.
- 543 7. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, et al. A major
544 role for ferroptosis in *Mycobacterium tuberculosis*-induced cell death and tissue necrosis. *J Exp*
545 *Med*. 2019;216(3):556-70.
- 546 8. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, et al. A major
547 role for ferroptosis in *Mycobacterium tuberculosis*-induced cell death and tissue necrosis. *Journal*
548 *of Experimental Medicine*. 2019;216(3):556-70.
- 549 9. Jaisinghani N, Dawa S, Singh K, Nandy A, Menon D, Bhandari PD, et al. Necrosis driven
550 triglyceride synthesis primes macrophages for inflammation during *Mycobacterium tuberculosis*
551 infection. *Frontiers in Immunology*. 2018;9:1490.
- 552 10. Lee J, Hartman M, Kornfeld H. Macrophage apoptosis in tuberculosis. *Yonsei medical*
553 *journal*. 2009;50(1):1-11.
- 554 11. Danelishvili L, McGarvey J, Li Yj, Bermudez LE. *Mycobacterium tuberculosis* infection causes
555 different levels of apoptosis and necrosis in human macrophages and alveolar epithelial cells.
556 *Cellular microbiology*. 2003;5(9):649-60.
- 557 12. Amaral EP, Ribeiro SC, Lanes VR, Almeida FM, de Andrade MR, Bomfim CCB, et al. Pulmonary
558 infection with hypervirulent *Mycobacteria* reveals a crucial role for the P2X7 receptor in aggressive
559 forms of tuberculosis. *PLoS pathogens*. 2014;10(7):e1004188.
- 560 13. Ribeiro SC, Gomes LL, Amaral EP, Andrade MR, Almeida FM, Rezende AL, et al.
561 *Mycobacterium tuberculosis* strains of the modern sublineage of the Beijing family are more likely
562 to display increased virulence than strains of the ancient sublineage. *Journal of clinical microbiology*.
563 2014;52(7):2615-24.
- 564 14. Santiago-Carvalho I, Almeida-Santos Gd, Bomfim CCB, Souza PCd, Silva JCSE, Melo BMSd, et
565 al. P2x7 receptor signaling blockade reduces lung inflammation and necrosis during severe
566 experimental tuberculosis. *Frontiers in Cellular and Infection Microbiology*. 2021;11:672472.
- 567 15. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer.
568 *Current opinion in pharmacology*. 2016;29:7-16.
- 569 16. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD 39 and CD 73: novel
570 checkpoint inhibitor targets. *Immunological reviews*. 2017;276(1):121-44.
- 571 17. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. *Nature*.
572 2014;509(7500):310-7.
- 573 18. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. *Naunyn-
574 Schmiedeberg's archives of pharmacology*. 2000;362.

- 575 19. Savio LEB, de Andrade Mello P, Figliuolo VR, de Avelar Almeida TF, Santana PT, Oliveira SD,
576 et al. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
577 *Journal of hepatology*. 2017;67(4):716-26.
- 578 20. Luo Y, Xue Y, Lin Q, Tang G, Song H, Liu W, et al. CD39 pathway inhibits Th1 cell function in
579 tuberculosis. *Immunology*. 2022;166(4):522-38.
- 580 21. Kim K, Perera R, Tan D, Fernandez S, Seddiki N, Waring J, et al. Circulating mycobacterial-
581 reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than
582 latent tuberculosis infection. *Tuberculosis*. 2014;94(5):494-501.
- 583 22. Cardona P, Cardona P-J. Regulatory T cells in *Mycobacterium tuberculosis* infection.
584 *Frontiers in immunology*. 2019;10:2139.
- 585 23. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
586 expression analyses for RNA-sequencing and microarray studies. *Nucleic acids research*.
587 2015;43(7):e47-e.
- 588 24. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in
589 multidimensional genomic data. *Bioinformatics*. 2016;32(18):2847-9.
- 590 25. Kassambara A. Visualization of a Correlation Matrix using “ggplot2.”. R package version 01.
591 2019;3.
- 592 26. Moreira-Teixeira L, Tabone O, Graham CM, Singhania A, Stavropoulos E, Redford PS, et al.
593 Mouse transcriptome reveals potential signatures of protection and pathogenesis in human
594 tuberculosis. *Nature immunology*. 2020;21(4):464-76.
- 595 27. Cellular ecology of *M. tuberculosis* granulomas (4 week dataset)ecology of *M. tuberculosis*
596 granulomas (4 week dataset). In: Institute B, editor.
- 597 28. Almeida FM, Ventura TL, Amaral EP, Ribeiro SC, Calixto SD, Manhaes MR, et al. Hypervirulent
598 *Mycobacterium tuberculosis* strain triggers necrotic lung pathology associated with enhanced
599 recruitment of neutrophils in resistant C57BL/6 mice. *PloS one*. 2017;12(3):e0173715.
- 600 29. Santiago-Carvalho I, Almeida-Santos G, Macedo BG, Barbosa-Bomfim CC, Almeida FM, Cione
601 MVP, et al. T cell-specific P2RX7 favors lung parenchymal CD4+ T cell accumulation in response to
602 severe lung infections. *Cell reports*. 2023;42(11).
- 603 30. Lévesque SA, Kukulski F, Enyoji K, Robson SC, Sévigny J. NTPDase1 governs P2X7-dependent
604 functions in murine macrophages. *European journal of immunology*. 2010;40(5):1473-85.
- 605 31. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung remodeling in
606 pulmonary tuberculosis. *The Journal of infectious diseases*. 2005;192(7):1201-10.
- 607 32. Dorhoi A, Kaufmann SHE. Pathology and immune reactivity: understanding
608 multidimensionality in pulmonary tuberculosis. *Seminars in Immunopathology*. 2016;38(2):153-66.
- 609 33. Bomfim CCB, Amaral EP, Cassado AdA, Salles ÉM, do Nascimento RS, Lasunskiaia E, et al.
610 P2X7 receptor in bone marrow-derived cells aggravates tuberculosis caused by hypervirulent
611 *Mycobacterium bovis*. *Frontiers in Immunology*. 2017;8:435.
- 612 34. Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure
613 function relationships and pathophysiological significance. *Purinergic signalling*. 2006;2:409-30.
- 614 35. Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and
615 inflammation. *Immunity*. 2017;47(1):15-31.
- 616 36. Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. *Nature*
617 *Reviews Clinical Oncology*. 2020;17(10):611-29.
- 618 37. Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy.
619 *Journal for immunotherapy of cancer*. 2020;8(1).
- 620 38. Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao C-C, et al.
621 Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. *Nature*
622 *neuroscience*. 2019;22(5):729-40.

- 623 39. Moesta AK, Li X-Y, Smyth MJ. Targeting CD39 in cancer. *Nature Reviews Immunology*.
624 2020;20(12):739-55.
- 625 40. Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, et al. Metabolic control
626 of type 1 regulatory T cell differentiation by AHR and HIF1- α . *Nature medicine*. 2015;21(6):638-46.
- 627 41. García-Hernández MH, Portales-Cervantes L, Cortez-Espinosa N, Vargas-Morales JM, Salazar
628 JFF, Rivera-López E, et al. Expression and function of P2X7 receptor and CD39/Entpd1 in patients
629 with type 2 diabetes and their association with biochemical parameters. *Cellular Immunology*.
630 2011;269(2):135-43.
- 631 42. Wang J, Sahoo M, Lantier L, Warawa J, Cordero H, Deobald K, et al. Caspase-11-dependent
632 pyroptosis of lung epithelial cells protects from melioidosis while caspase-1 mediates macrophage
633 pyroptosis and production of IL-18. *PLoS Pathog*. 2018;14(5):e1007105.
- 634 43. Amaral EP, Lasunskaja EB, D'Império-Lima MR. Innate immunity in tuberculosis: how the
635 sensing of mycobacteria and tissue damage modulates macrophage death. *Microbes Infect*.
636 2016;18(1):11-20.
- 637 44. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, et al. *Mycobacterium*
638 tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. *Nat Immunol*.
639 2009;10(8):899-906.
- 640 45. Borges da Silva H, Wang H, Qian LJ, Hogquist KA, Jameson SC. ARTC2. 2/P2RX7 signaling
641 during cell isolation distorts function and quantification of tissue-resident CD8+ T cell and invariant
642 NKT subsets. *The Journal of Immunology*. 2019;202(7):2153-63.
- 643 46. Rissiek B, Lukowiak M, Raczkowski F, Magnus T, Mittrücker H-W, Koch-Nolte F. In vivo
644 blockade of murine ARTC2. 2 during cell preparation preserves the vitality and function of liver
645 tissue-resident memory T cells. *Frontiers in Immunology*. 2018;9:1580.

646

647

648

649

650

651

652

653

654


655

656


657

658 SUPPLEMENTARY MATERIAL

A




B



659

660 **Supplementary Figure 1. Gate strategies for analyzing myeloid cells and CD4⁺ T cells are shown in mice infected with**
 661 **the M299 Mtb strain. (A) Gate strategies to evaluate macrophages (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁻, CD68⁺, CD64⁺),**
 662 **dendritic cells (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁻, CD68⁻, CD64⁻, CD11b⁺, MHCII⁺), monocytes (Live/Dead⁻, DUMP⁻,**
 663 **CD45⁺, Ly6G⁻, MHCII⁻, SSCLow, Ly6C⁺), and neutrophils (Live/Dead⁻, DUMP⁻, CD45⁺, Ly6G⁺) within the CD45⁺ DUMP⁻**
 664 **population are shown. (B) Gate strategies are shown to evaluate CD8⁺, CD4⁺ T cells, and i.v.⁻ (vascular) and i.v.⁺ (parenchymal)**
 665 **CD44⁺CD4⁺ T cells.**




666

667 **Supplementary Figure 1. CD39 deficiency does not affect the number of activated CD4 T cells in the lung**

668 **parenchyma or vasculature.** A) Numbers of CD4⁺ T cells. B) Numbers of CD8⁺ T cells. C) tSNE plots depict the distribution

669 of vascular and parenchymal CD4⁺ T cell subsets. C) Expression of markers that are expressed by those distinguished

670 subsets. D) Numbers of i.v.⁺ (vascular) and i.v.⁻ (parenchymal) CD44⁺CD4⁺ T cells and CD44⁺CD4⁺ T cells.



671

672 **Supplementary Figure 2. The strategy of inhibition of P2RX7 to prevent cell death during tissue processing to obtain**
 673 **cell suspensions.** A) Experimental design: 4 weeks post-infection, Mtb-infected mice were treated or not with Brilliant Blue G
 674 (BBG) 30 minutes before euthanasia. After 30 minutes of blockade, the mice were euthanized, and the lungs were collected
 675 for digestion in a Collagenase + DNA cocktail. B) Lung weight and C) Colony-forming units (CFU) of Mtb M299 in lung
 676 homogenates from infected mice. D) Representative plots of live and dead cell frequencies on treated (BBG+) and non-treated
 677 (BBG-) mice. E) Number of viable cells per lung. F) Frequency of live cells. G) Frequency of Dead cells. Significant differences
 678 between groups are indicated by $p < 0.05$. Significance levels are represented as follows: $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.001$

679 (**), and $p < 0.0001$ (****), determined by the Mann-Whitney non-parametric test. The data represents results from two
680 independent experiments with four mice per group.

681